LIVIVO - Search results -

Search results

Result 1 - 10 of total 40

Search options

Article ; Online: Reducing inpatient suicide rates: The success of a suicide management programme in a general hospital.

Ang, Lye Poh Aaron

2018 Volume 54, Page(s) 60–61

MeSH term(s)	Hospitals, General/statistics & numerical data ; Humans ; Inpatients/statistics & numerical data ; Outcome and Process Assessment (Health Care)/statistics & numerical data ; Program Development ; Quality Improvement ; Singapore ; Suicide/prevention & control ; Suicide/statistics & numerical data
Language	English
Publishing date	2018-05-17
Publishing country	United States
Document type	Letter
ZDB-ID	392299-6
ISSN	1873-7714 ; 0163-8343
ISSN (online)	1873-7714
ISSN	0163-8343
DOI	10.1016/j.genhosppsych.2018.05.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1584: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: G-quadruplex ligands as therapeutic agents against cancer, neurological disorders and viral infections.

Yan, Mock Phooi / Wee, Chua Eng / Yen, Khor Poh / Stevens, Aaron / Wai, Lam Kok

Future medicinal chemistry

2023 Volume 15, Issue 21, Page(s) 1987–2009

Abstract: G-quadruplexes (G4s) within the human genome have undergone extensive molecular investigation, with a strong focus on telomeres, gene promoters and repetitive regulatory sequences. G4s play central roles in regulating essential biological processes, ... ...

Abstract	G-quadruplexes (G4s) within the human genome have undergone extensive molecular investigation, with a strong focus on telomeres, gene promoters and repetitive regulatory sequences. G4s play central roles in regulating essential biological processes, including telomere maintenance, replication, transcription and translation. Targeting these molecular processes with G4-binding ligands holds substantial therapeutic potential in anticancer treatments and has also shown promise in treating neurological, skeletal and muscular disorders. The presence of G4s in bacterial and viral genomes also suggests that G4-binding ligands could be a critical tool in fighting infections. This review provides an overview of the progress and applications of G4-binding ligands, their proposed mechanisms of action, challenges faced and prospects for their utilization in anticancer treatments, neurological disorders and antiviral activities.
MeSH term(s)	Humans ; G-Quadruplexes ; Virus Diseases/drug therapy ; Neoplasms/drug therapy ; Nervous System Diseases/drug therapy ; Ligands ; Telomere
Chemical Substances	Ligands
Language	English
Publishing date	2023-11-07
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ISSN	1756-8927
ISSN (online)	1756-8927
DOI	10.4155/fmc-2023-0202
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Second primary malignancies in multiple myeloma: A review.

Poh, Christina / Keegan, Theresa / Rosenberg, Aaron Seth

Blood reviews

2020 Volume 46, Page(s) 100757

Abstract: As survival times of multiple myeloma (MM) patients continue to improve, second primary malignancies (SPM) have become an increasingly relevant long-term risk among MM survivors. Population studies since the 1950s have consistently observed an increased ... ...

Abstract	As survival times of multiple myeloma (MM) patients continue to improve, second primary malignancies (SPM) have become an increasingly relevant long-term risk among MM survivors. Population studies since the 1950s have consistently observed an increased incidence of hematologic SPMs, specifically acute leukemia, among MM survivors. Prolonged treatment with alkylators, especially melphalan, was associated with an increased hematologic SPM risk; likewise, autologous stem cell transplantation appeared to minimally increase SPM risk. Immunomodulatory drugs, specifically lenalidomide, was associated with an increased SPM incidence, although most studies concluded that the benefits of therapy outweighed any risks of SPM. Newer anti-myeloma therapy such as proteasome inhibitors and monoclonal antibodies did not appear to increase SPM risk although robust long-term follow-up is lacking. This review discusses current understanding regarding SPMs among survivors of MM, how different host-, disease- and treatment-related factors contribute to SPM incidence and highlights emerging screening guidelines and prognosis for SPMs.
MeSH term(s)	Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease Management ; Disease Susceptibility ; Humans ; Incidence ; Molecular Targeted Therapy/adverse effects ; Molecular Targeted Therapy/methods ; Multiple Myeloma/drug therapy ; Multiple Myeloma/epidemiology ; Neoplasms, Second Primary/epidemiology ; Neoplasms, Second Primary/etiology ; Population Surveillance ; Prognosis ; Risk Assessment ; Risk Factors
Chemical Substances	Antineoplastic Agents, Alkylating ; Antineoplastic Agents, Immunological
Language	English
Publishing date	2020-09-06
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	639015-8
ISSN	1532-1681 ; 0268-960X
ISSN (online)	1532-1681
ISSN	0268-960X
DOI	10.1016/j.blre.2020.100757
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2207: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Development of a novel gout treatment patient decision aid by patient and physician: A qualitative research study.

Meyappan, Meykkumar / Loh, Wei Siong Aaron / Tan, Li Yen / Tan, Sheng Feng Ian / Ho, Pey Ying / Poh, Yih Jia / Tan, Ngiap Chuan

Health expectations : an international journal of public participation in health care and health policy

2021 Volume 24, Issue 2, Page(s) 431–443

Abstract: Background: Gout treatment is not optimized globally, often due to therapeutic inertia by physicians or poor adherence to urate-lowering medications by patients. A patient decision aid (PDA) to facilitate shared decision making (SDM) in gout treatment ... ...

Abstract	Background: Gout treatment is not optimized globally, often due to therapeutic inertia by physicians or poor adherence to urate-lowering medications by patients. A patient decision aid (PDA) to facilitate shared decision making (SDM) in gout treatment may overcome these physician-patient barriers. Objective: The study explored the views of physicians and patients on a novel locally designed gout treatment PDA prototype. Design: Qualitative descriptive design was used to gather data from in-depth-interviews (IDI) and focus group discussions (FGD). Data analysis was via thematic analysis. Emergent themes shaped a revised version of the PDA. Setting and participants: Adult Asian patients with recent acute gout exacerbations and local Primary Care Physicians (PCP) in Singapore were purposefully chosen. 15 patients with gout and 11 PCPs participated across three IDIs and six FGDs, with the investigators exploring their views of a prototype gout treatment PDA. Results: Patients and physicians generally concurred with the content and design of the PDA prototype. However, while patients preferred fewer treatment details, the PCPs desired more information. Patients preferred the display of statistics, while PCPs felt that numbers were not relevant to patients. The latter were hesitant to include treatment options that were unavailable in primary care. Both stakeholders indicated that they would use the PDA during a consultation. PCPs would need further training in SDM, given a lack of understanding of it. Conclusion and patient contribution: Patients will be the prime users of the PDA. While their views differed partially from the physicians, both have jointly developed the novel gout treatment PDA.
MeSH term(s)	Adult ; Decision Making ; Decision Support Techniques ; Focus Groups ; Gout/drug therapy ; Humans ; Patient Participation ; Physicians, Primary Care ; Qualitative Research
Language	English
Publishing date	2021-01-12
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2119434-8
ISSN	1369-7625 ; 1369-6513
ISSN (online)	1369-7625
ISSN	1369-6513
DOI	10.1111/hex.13184
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5896: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Engineered Nucleotide Chemicapacitive Microsensor Array Augmented with Physics-Guided Machine Learning for High-Throughput Screening of Cannabidiol.

Yap, Stephanie Hui Kit / Pan, Jieming / Linh, Dao Viet / Zhang, Xiangyu / Wang, Xinghua / Teo, Wei Zhe / Zamburg, Evgeny / Tham, Chen-Khong / Yew, Wen Shan / Poh, Chueh Loo / Thean, Aaron Voon-Yew

Small (Weinheim an der Bergstrasse, Germany)

2022 Volume 18, Issue 22, Page(s) e2107659

Abstract: The recent legalization of cannabidiol (CBD) to treat neurological conditions such as epilepsy has sparked rising interest across global pharmaceuticals and synthetic biology industries to engineer microbes for sustainable synthetic production of ... ...

Abstract	The recent legalization of cannabidiol (CBD) to treat neurological conditions such as epilepsy has sparked rising interest across global pharmaceuticals and synthetic biology industries to engineer microbes for sustainable synthetic production of medicinal CBD. Since the process involves screening large amounts of samples, the main challenge is often associated with the conventional screening platform that is time consuming, and laborious with high operating costs. Here, a portable, high-throughput Aptamer-based BioSenSing System (ABS
MeSH term(s)	Cannabidiol/therapeutic use ; High-Throughput Screening Assays ; Machine Learning ; Nucleotides ; Physics
Chemical Substances	Nucleotides ; Cannabidiol (19GBJ60SN5)
Language	English
Publishing date	2022-05-06
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2168935-0
ISSN	1613-6829 ; 1613-6810
ISSN (online)	1613-6829
ISSN	1613-6810
DOI	10.1002/smll.202107659
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Tuscano, Joseph / Poh, Christina / Rosenberg, Aaron / Jonas, Brian / Abedi, Mehrdad / Barisone, Gustavo / Schwab, Emily / Lundeberg, Kathleen / Kaesberg, Paul

Journal of hematology

2020 Volume 9, Issue 3, Page(s) 79–83

Abstract: Background: While many humanized monoclonal antibodies utilize complement-dependent cytotoxicity, the complement depleting effects of these antibodies and the impact of complement replacement on treatment response are not well-described.: Methods: We ...

Abstract	Background: While many humanized monoclonal antibodies utilize complement-dependent cytotoxicity, the complement depleting effects of these antibodies and the impact of complement replacement on treatment response are not well-described. Methods: We conducted a phase 2 trial involving patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients were treated with ofatumumab with fresh frozen plasma (FFP) used as a source of complement replacement. The primary endpoint was objective response rate. Correlative endpoints included complement levels (C3 and C4) and complement activity (CH50) which was drawn at baseline and after ofatumumab with FFP administration. Results: Among 12 enrolled patients, overall response rate was 83% with two patients (17%) achieving a complete response. While only two (17%) patients had low complement activity at baseline, eight (67%) developed low levels of complement activity after ofatumumab treatment with FFP replacement. The magnitude of complement depletion did not correlate with response. Adverse events were minimal. The combination of ofatumumab and FFP demonstrated tolerability and surprising activity in high-risk CLL patients. Conclusions: The combination of ofatumumab and FFP demonstrated tolerability and surprising activity in high-risk CLL patients. Complement replacement should be studied further as a minimally toxic approach to improve efficacy of monoclonal antibody-based regimens.
Language	English
Publishing date	2020-08-14
Publishing country	Canada
Document type	Journal Article
ZDB-ID	2662519-2
ISSN	1927-1220 ; 1927-1220
ISSN (online)	1927-1220
ISSN	1927-1220
DOI	10.14740/jh721
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Importance of mental capacity: time for greater attention and action.

Ng, Peng Soon / Ang, Lye Poh Aaron / Kandiah, Nagaendran

Singapore medical journal

2015 Volume 56, Issue 12, Page(s) 646–648

MeSH term(s)	Cognition Disorders/diagnosis ; Decision Making ; Humans ; Mental Competency/legislation & jurisprudence ; Physicians ; Singapore
Language	English
Publishing date	2015-12
Publishing country	Singapore
Document type	Journal Article
ZDB-ID	604319-7
ISSN	0037-5675
ISSN	0037-5675
DOI	10.11622/smedj.2015182
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.B 589: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

Wong, Shi Yin / Lee, Ainsley Ryan Yan Bin / Sia, Aaron Hon Jiun / Wo, Yu Jun / Teo, Yao Hao / Teo, Yao Neng / Syn, Nicholas L / Ong, Ching-Ching / Teo, Lynette L / Yeo, Tiong-Cheng / Poh, Kian-Keong / Kong, William K / Wong, Raymond C / Sia, Ching-Hui

Cardiovascular drugs and therapy

2022 Volume 38, Issue 2, Page(s) 371–389

Abstract: Purpose: Recent trials suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and heart failure-related hospitalisations. We examined whether and how GLP- ... ...

Abstract	Purpose: Recent trials suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and heart failure-related hospitalisations. We examined whether and how GLP-1RAs affect cardiac function in cardiovascular and metabolic diseases including type 2 diabetes, heart failure and post-myocardial infarction. Methods: In this PRISMA-adherent systematic review and meta-analysis, three databases were searched from inception to July 2021 and registered on PROSPERO (CRD42021259661). Results: 20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed. Among type 2 diabetes patients, GLP-1RA resulted in improved systolic function measured by circumferential strain (mean difference [MD]= -5.48; 95% CI: -10.47 to -0.49; P= 0.03; I Conclusion: GLP-1RA drugs may improve systolic and diastolic function in type 2 diabetes and reduce infarct size post-acute myocardial infarction with no demonstrable effect on cardiac function in heart failure. Tailored recommendations for the use of GLP-1RAs for cardioprotection should be considered for each patient's condition.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Glucagon-Like Peptide-1 Receptor Agonists ; Stroke Volume ; Ventricular Function, Left ; Heart Failure/diagnosis ; Heart Failure/drug therapy ; Myocardial Infarction/drug therapy ; Infarction/chemically induced ; Glucagon-Like Peptide-1 Receptor/agonists ; Randomized Controlled Trials as Topic
Chemical Substances	Hypoglycemic Agents ; Glucagon-Like Peptide-1 Receptor Agonists ; Glucagon-Like Peptide-1 Receptor
Language	English
Publishing date	2022-07-12
Publishing country	United States
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Review
ZDB-ID	639068-7
ISSN	1573-7241 ; 0920-3206
ISSN (online)	1573-7241
ISSN	0920-3206
DOI	10.1007/s10557-022-07360-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 3057: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.

Tuscano, Joseph M / Poh, Christina / Kaesberg, Paul / Luxardi, Guilluame / Merleev, Alexander / Marusina, Alina / Brunson, Ann / Rosenberg, Aaron / Jonas, Brian / Maverakis, Emanual

Clinical cancer research : an official journal of the American Association for Cancer Research

2021 Volume 27, Issue 17, Page(s) 4726–4736

Abstract: Purpose: Rituximab and lenalidomide are effective for previously untreated and relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, long-term survival and predictive biomarkers are not well described.: Patients and methods: We ... ...

Abstract	Purpose: Rituximab and lenalidomide are effective for previously untreated and relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, long-term survival and predictive biomarkers are not well described. Patients and methods: We conducted two phase II open-label trials involving 60 patients with previously untreated and R/R advanced-stage iNHL. Patients received lenalidomide and rituximab induction followed by continuous lenalidomide until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Correlative studies included plasma cytokine monitoring, flow cytometry of peripheral blood mononuclear cells (PBMC; days 0, 15, 30, and 60), and RNA sequencing (RNA-seq) of pretreatment tumor biopsies. Results: At a median follow-up of 63 months for previously untreated and 100 months for R/R, ORR was 82% for both. The 11 R/R patients who achieved complete remission remained in continuous remission for 16 to 141 months, thereafter. Median overall survival (OS) was not reached in the previously untreated and was 140 months (95% confidence interval, 53.4-140) in the R/R group. A mixed-effects linear regression model identified significant associations between Granzyme B Conclusions: Rituximab plus lenalidomide followed by continuous lenalidomide is effective with manageable toxicity in patients with previously untreated and R/R iNHL. This regimen produces durable remissions, even in heavily pretreated patients, with some lasting greater than 10 years. GranB
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CD8-Positive T-Lymphocytes ; Follow-Up Studies ; Humans ; Lenalidomide ; Leukocytes, Mononuclear ; Lymphoma, Non-Hodgkin/drug therapy ; Rituximab/therapeutic use
Chemical Substances	Rituximab (4F4X42SYQ6) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2021-06-04
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Comment
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-20-4622
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ultrahigh resolution retinal imaging by visible light OCT with longitudinal achromatization.

Chong, Shau Poh / Zhang, Tingwei / Kho, Aaron / Bernucci, Marcel T / Dubra, Alfredo / Srinivasan, Vivek J

Biomedical optics express

2018 Volume 9, Issue 4, Page(s) 1477–1491

Abstract: Chromatic aberrations are an important design consideration in high resolution, high bandwidth, refractive imaging systems that use visible light. Here, we present a fiber-based spectral/Fourier domain, visible light OCT ophthalmoscope corrected for the ... ...

Abstract	Chromatic aberrations are an important design consideration in high resolution, high bandwidth, refractive imaging systems that use visible light. Here, we present a fiber-based spectral/Fourier domain, visible light OCT ophthalmoscope corrected for the average longitudinal chromatic aberration (LCA) of the human eye. Analysis of complex speckles from
Language	English
Publishing date	2018-03-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	2572216-5
ISSN	2156-7085
ISSN	2156-7085
DOI	10.1364/BOE.9.001477
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito